Sana Biotech announces two exec appointments

11 April 2023

USA-based Sana Biotechnology (Nasdaq: SANA) has announced the appointments of two senior leaders to its research and development organization.

Douglas Williams has been named as president of R&D, and Dr Gary Meininger, as chief medical officer. In a planned transition, current CMO Dr Sunil Agarwal will leave the company after helping onboard these new executives.

Dr Williams has over three decades of experience leading R&D organizations and companies, including at Biogen (Nasdaq: BIIB), ZymoGenetics, Seattle Genetics, Amgen (Nasdaq: AMGN), and Immunex, and most recently he was chief executive of Codiak BioSciences, which last month filed for Chapter 11 bankruptcy. In his career, he has participated in the development of over a dozen approved medicines across multiple therapeutic areas, including multiple blockbusters.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK